An Expanded Access Program of Tarceva (Erlotinib) in Participants With Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT00949910 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

6586

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: Erlotinib

Sponsor

Hoffmann-La Roche